💊 STOCK TO WATCH 💊
₹1,060–1,070 → ₹1,462 → ₹2,888 👀
A pharma/CDMO name appearing on my Weekly R4 Momentum Breakout Scanner.
Windlas Biotech Ltd.
📌 Buy Zone: ₹1,060–1,070
📌 Breakout Zone: ₹1,056
🛑 Stop Loss: ₹751
🎯 Target 1: ₹1,462
🎯 Target 2: ₹2,888
Why Windlas Biotech?
🧬 CDMO + formulations play: Windlas operates across generic formulations CDMO, domestic trade generics/institutional sales and exports, giving it multiple revenue engines.
🌍 Growing export opportunity: FY25 export revenue grew 19% YoY to ₹32.6 Cr, with 69 products exported to global partners.
🏭 Regulated manufacturing base: Its facilities include WHO-GMP-approved plants, with Plant 4 approved for markets including Europe, Canada and South Africa; Plant 5 adds injectable manufacturing capability.
💊 Complex-generic opportunity: The company is expanding product-development and manufacturing capabilities in complex generics and specialised dosage forms.
📈 Strong operating track record: Windlas reported Q1 FY26 revenue of ₹210 Cr, EBITDA ₹27 Cr and PAT ₹18 Cr, with YoY growth of 20%, 27% and 31%, respectively.
Why It Caught My Attention
✅ CDMO + branded formulations + exports
✅ Complex-generic opportunity
✅ WHO-GMP manufacturing infrastructure
✅ Injectable manufacturing capability
✅ Growing international presence
✅ Strong recent operating momentum
🔥 Weekly R4 Momentum Breakout
⚠️ HIGH RISK – HIGH REWARD SETUP. The technical levels above are your scanner-defined levels. The ₹751 stop-loss should be treated as the risk-control point, while execution, margins and export growth need continued monitoring.
Risk Defined. Reward Visible.
📢 Disclaimer: This content is for educational purposes only and not investment advice. Please do your own due diligence before making any investment decisions.
© 20K Microcap Investing | R4 Momentum Desk
#WindlasBiotech #WINDLASS #PharmaStocks #CDMO #PharmaceuticalStocks #ComplexGenerics #SmallCapStocks #HealthcareStocks #StockMarketIndia #IndianStocks #StocksToWatch #R4Breakout #MomentumInvesting #20KMicrocap
₹1,060–1,070 → ₹1,462 → ₹2,888 👀
A pharma/CDMO name appearing on my Weekly R4 Momentum Breakout Scanner.
Windlas Biotech Ltd.
📌 Buy Zone: ₹1,060–1,070
📌 Breakout Zone: ₹1,056
🛑 Stop Loss: ₹751
🎯 Target 1: ₹1,462
🎯 Target 2: ₹2,888
Why Windlas Biotech?
🧬 CDMO + formulations play: Windlas operates across generic formulations CDMO, domestic trade generics/institutional sales and exports, giving it multiple revenue engines.
🌍 Growing export opportunity: FY25 export revenue grew 19% YoY to ₹32.6 Cr, with 69 products exported to global partners.
🏭 Regulated manufacturing base: Its facilities include WHO-GMP-approved plants, with Plant 4 approved for markets including Europe, Canada and South Africa; Plant 5 adds injectable manufacturing capability.
💊 Complex-generic opportunity: The company is expanding product-development and manufacturing capabilities in complex generics and specialised dosage forms.
📈 Strong operating track record: Windlas reported Q1 FY26 revenue of ₹210 Cr, EBITDA ₹27 Cr and PAT ₹18 Cr, with YoY growth of 20%, 27% and 31%, respectively.
Why It Caught My Attention
✅ CDMO + branded formulations + exports
✅ Complex-generic opportunity
✅ WHO-GMP manufacturing infrastructure
✅ Injectable manufacturing capability
✅ Growing international presence
✅ Strong recent operating momentum
🔥 Weekly R4 Momentum Breakout
⚠️ HIGH RISK – HIGH REWARD SETUP. The technical levels above are your scanner-defined levels. The ₹751 stop-loss should be treated as the risk-control point, while execution, margins and export growth need continued monitoring.
Risk Defined. Reward Visible.
📢 Disclaimer: This content is for educational purposes only and not investment advice. Please do your own due diligence before making any investment decisions.
© 20K Microcap Investing | R4 Momentum Desk
#WindlasBiotech #WINDLASS #PharmaStocks #CDMO #PharmaceuticalStocks #ComplexGenerics #SmallCapStocks #HealthcareStocks #StockMarketIndia #IndianStocks #StocksToWatch #R4Breakout #MomentumInvesting #20KMicrocap
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.